Free Trial
NASDAQ:CODX

Co-Diagnostics (CODX) Stock Price, News & Analysis

Co-Diagnostics logo
$0.26 -0.01 (-4.00%)
As of 03:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Co-Diagnostics Stock (NASDAQ:CODX)

Key Stats

Today's Range
$0.25
$0.29
50-Day Range
$0.28
$0.49
52-Week Range
$0.25
$2.23
Volume
515,596 shs
Average Volume
219,330 shs
Market Capitalization
$8.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50
Consensus Rating
Buy

Company Overview

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Co-Diagnostics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
85th Percentile Overall Score

CODX MarketRank™: 

Co-Diagnostics scored higher than 85% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Co-Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Co-Diagnostics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Co-Diagnostics' stock forecast and price target.
  • Earnings Growth

    Earnings for Co-Diagnostics are expected to grow in the coming year, from ($1.22) to ($1.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Co-Diagnostics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Co-Diagnostics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Co-Diagnostics has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.41% of the outstanding shares of Co-Diagnostics have been sold short.
  • Short Interest Ratio / Days to Cover

    Co-Diagnostics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Co-Diagnostics has recently decreased by 3.94%, indicating that investor sentiment is improving.
  • Dividend Yield

    Co-Diagnostics does not currently pay a dividend.

  • Dividend Growth

    Co-Diagnostics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.41% of the outstanding shares of Co-Diagnostics have been sold short.
  • Short Interest Ratio / Days to Cover

    Co-Diagnostics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Co-Diagnostics has recently decreased by 3.94%, indicating that investor sentiment is improving.
  • News Sentiment

    Co-Diagnostics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Co-Diagnostics this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for CODX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Co-Diagnostics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.40% of the stock of Co-Diagnostics is held by insiders.

  • Percentage Held by Institutions

    Only 14.99% of the stock of Co-Diagnostics is held by institutions.

  • Read more about Co-Diagnostics' insider trading history.
Receive CODX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CODX Stock News Headlines

Q2 EPS Estimates for Co-Diagnostics Lifted by HC Wainwright
HC Wainwright Predicts Co-Diagnostics Q1 Earnings
Washington Is Broke—and Eyeing Your Savings Next
Washington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.
See More Headlines

CODX Stock Analysis - Frequently Asked Questions

Co-Diagnostics' stock was trading at $0.75 at the beginning of 2025. Since then, CODX stock has decreased by 64.8% and is now trading at $0.2640.
View the best growth stocks for 2025 here
.

Co-Diagnostics, Inc. (NASDAQ:CODX) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.09. The business earned $0.05 million during the quarter, compared to analyst estimates of $0.38 million. Co-Diagnostics had a negative trailing twelve-month return on equity of 54.94% and a negative net margin of 563.93%.
Read the conference call transcript
.

Co-Diagnostics (CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

Co-Diagnostics' top institutional shareholders include Simplex Trading LLC.
View institutional ownership trends
.

Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Co-Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Company Calendar

Last Earnings
5/08/2025
Today
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:CODX
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$10.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+1,944.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,330,000.00
Net Margins
-563.93%
Pretax Margin
-510.65%

Debt

Sales & Book Value

Annual Sales
$3.71 million
Price / Cash Flow
N/A
Book Value
$2.81 per share
Price / Book
0.10

Miscellaneous

Free Float
29,982,000
Market Cap
$9.03 million
Optionable
Optionable
Beta
0.84

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:CODX) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners